Table 1.

Baseline characteristics

Age, years [median (range)]	58 (34–77)
Sex [n (%)]
Male Female	30 (57.7) 22 (42.3)
BMI [median (range)]	24.4 (17.8–35.4)
Liver metastasis [n (%)]
One Two Multiple	9 (17.3) 5 (9.6) 38 (73.1)
Tumor location [n (%)]
Head Body and tail	36 (69.2) 16 (30.7)
Primary tumor resectability at diagnosis [n (%)]
Resectable	28 (54.2)
BLR/LAPC	24 (45.8)
Primary chemotherapy regimen [n (%)]
FOLFIRINOX	33 (63.5)
Gemcitabine + nab-paclitaxel	14 (26.9)
Gemcitabine	5 (9.6)
Chemotherapy cycles [median (range)]	9.4 (1–20)
CA19-9, U/mL [median (range)] Baseline Restaging Normal value before surgery [n (%)]	p < 0.001 1167.2 (0.6–9824) 50.6 (0.6–277) 35 (67.3)
CEA, ng/mL [median (range)] Baseline Re-staging	p < 0.042 32.7 (16-45) 17.6 (0-37)

Significant results (p < 0.05) are highlighted in bold

BMI body mass index, BLR borderline resectable, LAPC locally advanced pancreatic cancer, CA carbohydrate antigen, CEA carcinoembryonic antigen